The Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities

References

1. ↵
   Gross JL, Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovits T. Diabetic nephropathy: diagnosis, prevention and treament. Diabetes Care 2005; 28: 176–88.

   OpenUrl
2. ↵
   Resnick HE, Foster GL, Bardlsey J, Ratner RE. Achievement of American Diabetes Assocation Clinical Practice Recommendations among US adults with diabetes, 1999–2002: The National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531–7.

   OpenUrlAbstract/FREE Full Text
3. ↵
   American Diabetes Association. Diabetes and nephropathy (kidney complications). Available at: http://www.diabetes.org/diabetes-statistics/kidney-disease.jsp. Accessed July 7, 2009.
4. ↵
   Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1–S201.

   OpenUrlPubMed
6. ↵
   Klaus G. Renoprotection with vitamin D: specific for diabetic nephropathy? Kidney Int 2008; 73: 141–3.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163–71.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526–33.

   OpenUrlAbstract/FREE Full Text
9. ↵
   Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696–705.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266–75.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Harris SS. Vitamin D and African Americans. J Nutr 2006; 136: 1126–9.

    OpenUrlAbstract/FREE Full Text
12. ↵
    Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30: 771–7.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Centers for Disease Control and Prevention, National Center for Health Statistics. NHANES Analytic Guidelines. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_general_guidelines_june_04.pdf.2004. Accessed February 3, 2009.
14. ↵
    Molitch ME, DeFronzo FA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79–83.

    OpenUrlCrossRefPubMed
15. ↵
    Centers for Disease Control and Prevention, National Center for Health Statistics. NHANES 1999–2000 Data Release. Prescription medication subsection (RXQ_RX) of dietary supplements and prescription medication section (DSQ) sample person questionnaire. Available at: www.cdc.gov/nchs/data/nhanes/frequency/rxq_rxdoc.pdf. Accessed July 7, 2009.
16. ↵
    Centers for Disease Control and Prevention, National Center for Health Statistics. NHANES 2001–2002 data documentation. April 2005 SP questionnaire. Prescription medication subsection (RXQ_RX_B) of dietary supplements and prescription medication section (DSQ). Available at: www.cdc.gov/nchs/data/nhanes/nhanes_01_02/rxq_rx_b_doc.pdf. Accessed July 7, 2009.
17. ↵
    Varughese GI, Lip GY. Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists’ Collaboration meta-analysis. J Hum Hypertens 2005; 19: 851–3.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126–31.

    OpenUrlAbstract/FREE Full Text
20. ↵
    Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003; 26: 911–6.

    OpenUrlAbstract/FREE Full Text
21. ↵
    Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730–7.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871–7.

    OpenUrlCrossRefPubMedWeb of Science
23. Grundy SM, Howard BS, Sidney ER Jr, Robert R, Rita Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231–9.

    OpenUrlFREE Full Text
24. Bertoni AG, Sayda S, Brancati FL. Diabetes and the risk of infection- related mortality in the US. Diabetes Care 2001; 24: 1044–9.

    OpenUrlAbstract/FREE Full Text
25. ↵
    Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317–22.

    OpenUrlAbstract/FREE Full Text